scholarly journals Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis

Pharmacy ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 215
Author(s):  
Trisha Zeidan ◽  
Carla Nikkel ◽  
Beth Dziengelewski ◽  
Stephanie Wu ◽  
Aleda M. H. Chen

Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (−1.5 ± 1.79%; p < 0.001). Patients prescribed insulin at baseline (n = 122) used significantly less insulin TDD (−8 u/day; p = 0.006). The percentage of patients meeting the target of A1C < 8% increased from 14% at baseline to 48% at study completion (p = 0.008). Patients prescribed a basal-bolus regimen prior to V-Go achieved an A1C reduction of 1.5 ± 2.0% (p < 0.0001) and experienced the greatest reduction in TDD (−24 u/day; p < 0.0001). Thus, patients switching to V-Go from a variety of therapies at baseline experienced reductions in A1C while using less insulin, with a reduction in clinically relevant hypoglycemia, indicating the potential benefit of V-Go in optimizing and simplifying T2D care.

2017 ◽  
Vol 6 (8) ◽  
pp. 748-757 ◽  
Author(s):  
Jothydev Kesavadev ◽  
Pradeep Babu Sadasivan Pillai ◽  
Arun Shankar ◽  
Gopika Krishnan ◽  
Sunitha Jothydev

Objective To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study). Research design and methods This 24-week, controlled, open-label study randomized T2DM patients (n = 440) receiving a stable dose of metformin and insulin combination therapy to sitagliptin (100 mg) or glimepiride (1–3 mg) as add-on therapy. Baseline HbA1c was ≥7.3% and ≤8.5%. After a 6-week titration period for glimepiride (dose titrated every 2 weeks by 1 mg up to a maximum of 3 mg daily), patients were continued for 18 weeks on their respective tolerable doses of glimepiride (ranging from 1 mg to 3 mg) or sitagliptin (100 mg) along with metformin and insulin. Results Greater reductions in HbA1c and TDD of insulin were achieved with sitagliptin compared to glimepiride. HbA1c targets and reductions in TDD were achieved by more patients on sitagliptin than on glimepiride. Reductions in both body weight and BMI were also noted among patients on sitagliptin when compared to those on glimepiride, and more hypoglycemic events occurred with glimepiride treatment than with sitagliptin. Conclusions Sitagliptin (100 mg), when compared to glimepiride (1–3 mg), bestowed beneficial effects to T2DM patients in terms of achieving greater glycemic control and also brought significant reductions in total daily dose of insulin required, bodyweight, BMI and hypoglycemic events. Overall, the results suggest that sitagliptin (100 mg) is a superior agent over glimepiride (1–3 mg) as an add-on to insulin–metformin therapy among Asian Indians with T2DM.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 989-P
Author(s):  
RIPU S. HUNDAL ◽  
STEPHAN KOWALYK ◽  
JANE CASES ◽  
AMER AL-KARADSHEH ◽  
AMANDA P. WAKIM ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2273-PUB
Author(s):  
THOMAS LUDDEN ◽  
ANASTASIA ERMAKOVA ◽  
YAN XIONG ◽  
RAY SIERADZAN ◽  
NAOMI C. SACKS ◽  
...  

2016 ◽  
Vol 22 (6) ◽  
pp. 653-665 ◽  
Author(s):  
Carol Wysham ◽  
Robert C. Hood ◽  
Mark L. Warren ◽  
Tao Wang ◽  
Tina M. Morwick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document